loader2
Partner With Us NRI

Company details

38.25
40.45
36.45
115.10
6M Return -35.85%
1Y Return -38.70%
Mkt Cap.(Cr) 59.51
Volume 6,636
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 6,636

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 41.10 Cr FV: 10.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,806.36 -39,994.59
LAST 3M 79,235.45 -52,306.79
LAST 6M 143,739.24 -201,556.99
LAST 12M 206,053.08 -176,593.86

Information

  • About Company
  • Company Info
  • Listing Info
18.71
42.16%
32.6098
18.65%
15.03%
Description
  • Vivo Bio Tech is a full service CRO offering drug development & discovery services to pharmaceutical & biotech companies world-wide in accordance with OECD, AAALAC & IND guidelines. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetics & toxicokinetic studies etc. Our experienced & talented scientists offer advice on defining drug development paths tailored to specific molecules. Tailored and dedicated to our clients, we distinguish your development plan is as superlative as the products you bring to our testing facilities. The Biologic Research Services group at Vivo Bio Tech offers a complete line of protein services, including gene synthesis, cloning, expression and purification of recombinant proteins and monoclonal antibodies. Our scientists will team up with you to develop solution for the most difficult to deal products including purification of untagged & poorly expressed proteins. In-vitro Services offers solutions for pharmacologic, toxicological & bioanalytical investigations in drug discovery & development. Critical investigations like bacterial reverse mutation assays, chromosomal aberration, and micronucleus are specialty services by our scientists. The In-vivo Services group at Vivo Bio Tech provides both non-regulatory and regulatory IND enabling preclinical development services. We are capable of screening & evaluating molecules for various pharmacological & therapeutic properties. Specifically for oncology, our scientists can provide design & development of xenograft models for evaluation of anti-cancer agents. Further, our scientists can customize in-vivo DMPK studies to help profile your drug candidate in both rodent and non-rodent animal models. Vivo Bio has partnered with Taconic for sourcing foundation and expansion colonies of the animal models and have started in-house breeding of Specific Pathogen Free rodents.

Read More

Registered Address

Survey #349/A Pregnapur Vlge, , Gajel, Telangana, 502311

Email : investors:vivobio.com
Website : http://www.vivobio.com

Registrar

Aarthi Consultants Pvt Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 10
Market Lot Equity Shares : 100
BSE Code : 511509
NSE Code :
Book Closure Date (Month) : Sep
BSE Group : X
ISIN : INE380K01017

ICICIdirect Vivo Bio Tech Ltd FAQ

You can buy Vivo Bio Tech Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Vivo Bio Tech Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 20, 2022 04:01 PM the closing price of Vivo Bio Tech Ltd was ₹ 40.00.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 20, 2022 04:01 PM, the market cap of Vivo Bio Tech Ltd stood at ₹ 59.51.
The latest PE ratio of Vivo Bio Tech Ltd as of May 20, 2022 04:01 PM is 18.71
The latest PB ratio of Vivo Bio Tech Ltd as of May 20, 2022 04:01 PM is 0.82
The 52-week high of Vivo Bio Tech Ltd is ₹ 115.10 while the 52-week low is ₹ 36.45 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE